A team at the University of Geneva has designed a molecular system that identifies and neutralizes cancer cells with unprecedented precision, paving the way for autonomous, self-regulating drugs.
Using synthetic DNA strands, this smart system recognizes cancer cells with great precision and releases powerful drugs only where they are needed.
Beyond cancer treatment, this research paves the way for “smart” medicines and programmable drug delivery.
A paper corresponding to this research is published in Nature Biotechnology.
Directly targeting cancer cells could change treatments
The ability to directly target tumor cells with drugs could transform cancer treatment, preserve healthy tissue, and reduce the severe side effects associated with chemotherapy.
Among the most promising approaches in recent decades are antibody-drug conjugates (ADCs), which use monoclonal antibodies to precisely deliver therapeutic agents to cancer cells.
Despite their remarkable success, ADCs still face significant limitations, such as poor tumor tissue penetration and limited ability to deliver drug payloads.
DNA strands help overcome difficulties
In this new system, independent DNA strands carry different components, including two different cancer target binding agents and a cytotoxic drug.
When two specific cancer markers bind to their respective DNA-binding binders, the components self-assemble precisely at the tumor site.
This assembly allows multiple DNA fragments to be amplified by joining together at desired locations, allowing for the delivery of higher concentrations of drug.
Similar to two-factor authentication for banking websites, this process only occurs if both cancer markers are present. If either marker is missing, the hybridization chain reaction cannot be initiated and the drug remains inactive.
“This could be an important step in the evolution of medicine by introducing self-actuating drug systems,” explains Professor Nicholas Winsinger of the Department of Organic Chemistry, Faculty of Chemistry and Biochemistry, Faculty of Science, UNIGE.
“Historically, computers and AI have helped design new drugs. What is new here is that the drugs themselves can ‘compute’ biological signals in a simple way and respond intelligently.”
The future of autonomous drugs
Just as computers are built on the simple logical operations of “and,” “or,” and “not,” this technology applies the same principles at the molecular level.
In this first demonstration, an “and” logic gate ensures activation only in the presence of two cancer biomarkers, resulting in high drug selectivity.
In the future, future systems may integrate additional logical operations to create medicines that behave like programmable systems and can make complex decisions within the body.
This opens the door to truly “smart” medicines that adapt to the environment and tailor treatment to each patient’s unique physiology while minimizing side effects.
These innovations do not replace human surveillance, but aim to make treatments more targeted and effective, bring new hope to personalized care, and transform the way we fight disease.
Source link
